Banglahunt Desk: Corona virus epidemic is going on all over the world. The death toll is increasing day by day. The number of victims is increasing as well. And to prevent this catastrophe, scientists are working day and night to create a vaccine.
India is all set to make a global vaccine in New Delhi, IITG said. Many large pharma companies are trying to find a cure for coronavirus worldwide. That is why he is trying to make a vaccine inside a big laboratory. The catastrophe that is facing the world today can only end with the successful use of vaccines. Hester Biosciences has also announced the development of a corona vaccine. Following the announcement, its shares rose 20 percent on Wednesday.
Ahmedabad-based pharmaceutical company Hester Biosense said on Wednesday that it would develop the COVD-19 vaccine in collaboration with the Indian Institute of Technology Guwahati (Institute Guwahati). It is noteworthy that earlier, the Pune Serum Institute had claimed that it would bring the coronavirus vaccine between September-October, which would cost around Rs 1,000. On April 15, 2020, it announced an agreement with IITs. The vaccine will be based on the recombinant avian paramyxovirus vector platform.
RI Gandhi, CEO and MD of Bioscience, said, “Both IIT Guwahati and Hoster will co-operate in the development and construction of a vaccine to eradicate Covid-19. Hyster is involved in everything from the development of master seeds to the release of vaccines in commercial form. Shares of Hester Biosciences rose in the stock market on Wednesday and had to leave the upper circuit at 20%. Its shares were offered at Rs 1.38 on the BSE. Shares of the Ahmedabad-based pharmaceutical company have risen about 35 per cent in one month.
According to the statement, recombinant avian paramyxovirus-1 will be used as an immunologic protein of SARS-COV-2. Later it can be used for further study. Sachin Kumar, an associate professor in the Department of Biology and Biotechnology at IIT Guwahati, said it was too early to comment on the possibility of the vaccine. He will be the head of the research team.
It is noteworthy that earlier, Adar Punawala, CEO of the Pune Serum Institute for Coronary Vaccine in India, said that if the test is successful, the vaccine could come in September or October this year and be available for Rs 1,000. Punawala said he would try to make the corona vaccine at risk before pre-testing and that it would cost Rs 1,000 per vaccine if it was ready. It is noteworthy that all the big countries like America, where the technological advancement is the most, are also confident in India today, as Indian pharmaceutical companies are constantly trying to make vaccines. And the WHO added that Indian companies have experts who can help develop the Covid-19 vaccine.